In this week’s edition of InnovationRx, we look at the impact of Medicaid cuts, a $400 million obesity bet, a study of bias ...

IDEAYA Biosciences', a developmental biotech, valuation declined over 50% since mid-2024. Check out why I'm coming away with ...

Merck & Co – known as MSD outside of the US and Canada – and Cyprumed have entered into a partnership aimed at developing ...

According to DelveInsight's analysis, the market for GIST is anticipated to increase during the forecast period (2025–2034), owing to the launch of e ...

Merck signs deal with Austria's Cyprumed to develop oral peptide therapies, potentially paying up to $493 million for access ...

Learn more about whether Neurocrine Biosciences, Inc. or TG Therapeutics, Inc. is a better investment based on AAII's A+ ...

Explore how innovation, R&D, and policy reforms are reshaping China’s pharmaceutical sector amid rising healthcare demand and demographic shifts.

Jiangsu Hengrui Pharmaceuticals Co Ltd, a global pharmaceutical company focusing on scientific and technological innovation, announced on March 25 that it has entered into an exclusive license ...

Kailera jumped the weight loss miracle-drug line by licensing four clinical-stage obesity therapies from China, which is ...

Bristol Myers Squibb has received the FDA’s green light to introduce another immunotherapy-based treatment in first-line ...